UK markets closed

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS)

Shanghai - Shanghai Delayed price. Currency in CNY
Add to watchlist
13.90+0.06 (+0.43%)
At close: 03:00PM CST
Currency in CNY

Valuation measures4

Market cap (intra-day) 22.47B
Enterprise value 23.04B
Trailing P/E 17.33
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.08
Price/book (mrq)3.76
Enterprise value/revenue 7.06
Enterprise value/EBITDA 19.20

Trading information

Stock price history

Beta (5Y monthly) 0.36
52-week change 3-2.11%
S&P500 52-week change 326.27%
52-week high 316.40
52-week low 310.75
50-day moving average 312.70
200-day moving average 313.25

Share statistics

Avg vol (3-month) 311.87M
Avg vol (10-day) 38.93M
Shares outstanding 51.62B
Implied shares outstanding 61.62B
Float 8436.48M
% held by insiders 173.24%
% held by institutions 19.83%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.12
Forward annual dividend yield 40.83%
Trailing annual dividend rate 30.10
Trailing annual dividend yield 30.72%
5-year average dividend yield 4N/A
Payout ratio 418.25%
Dividend date 3N/A
Ex-dividend date 407 Jul 2023
Last split factor 21.3:1
Last split date 311 Jul 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -9.50%
Operating margin (ttm)19.91%

Management effectiveness

Return on assets (ttm)-3.39%
Return on equity (ttm)-5.52%

Income statement

Revenue (ttm)3.63B
Revenue per share (ttm)2.29
Quarterly revenue growth (yoy)-23.20%
Gross profit (ttm)N/A
EBITDA -398.28M
Net income avi to common (ttm)-344.58M
Diluted EPS (ttm)-0.22
Quarterly earnings growth (yoy)-46.70%

Balance sheet

Total cash (mrq)2.16B
Total cash per share (mrq)1.34
Total debt (mrq)2.73B
Total debt/equity (mrq)45.64%
Current ratio (mrq)2.45
Book value per share (mrq)3.71

Cash flow statement

Operating cash flow (ttm)1.7B
Levered free cash flow (ttm)1.34B